Difference between revisions of "LINC00520"
| Line 1: | Line 1: | ||
==Annotated Information== | ==Annotated Information== | ||
| − | [[File:LINC00520 is regulated by the PI3K pathway.jpg|right|thumb| | + | [[File:LINC00520 is regulated by the PI3K pathway.jpg|right|thumb|300px|'''LINC00520 is regulated by the PI3K pathway'''<ref name="ref1" />]] |
| − | [[File:Expression Analysis in Clinical Samples of Human Breast Invasive Carcinoma.jpg|right|thumb| | + | [[File:Expression Analysis in Clinical Samples of Human Breast Invasive Carcinoma.jpg|right|thumb|300px|'''Expression Analysis in Clinical Samples of Human Breast Invasive Carcinoma'''<ref name="ref1" />]] |
===Approved Symbol=== | ===Approved Symbol=== | ||
LINC00520 (long intergenic non-protein coding RNA 520) | LINC00520 (long intergenic non-protein coding RNA 520) | ||
| Line 10: | Line 10: | ||
===RefSeq(supplied by NCBI)=== | ===RefSeq(supplied by NCBI)=== | ||
NR_026796 | NR_026796 | ||
| − | |||
| − | |||
===Characteristics=== | ===Characteristics=== | ||
LINC00520 resides ~112kb from the kinesin receptor KTN1 and ~ 321kb from the Pellino E3 ubiquitin ligase family member 2, PELI2.<ref name="ref1" /> | LINC00520 resides ~112kb from the kinesin receptor KTN1 and ~ 321kb from the Pellino E3 ubiquitin ligase family member 2, PELI2.<ref name="ref1" /> | ||
Latest revision as of 12:47, 28 October 2017
Contents
Annotated Information
LINC00520 is regulated by the PI3K pathway[1]
Expression Analysis in Clinical Samples of Human Breast Invasive Carcinoma[1]
Approved Symbol
LINC00520 (long intergenic non-protein coding RNA 520)
Previous Symbols
C14orf34
Chromosome
14q22.3
RefSeq(supplied by NCBI)
NR_026796
Characteristics
LINC00520 resides ~112kb from the kinesin receptor KTN1 and ~ 321kb from the Pellino E3 ubiquitin ligase family member 2, PELI2.[1]
Disease
breast cancer
Regulation
LINC00520 is regulated by STAT3 and the PI3K pathway in Src-transformed cells.[1]
Function
shRNA-mediated loss-of-function studies shows LINC00520 play roles in cell migration and invasion.[1] Overexpression of LINC00520 results in alterations in global gene expression.[1]
Expression
Compared with the wild-type PIK3CA-expressing cells, increased LINC00520 transcript levels are observed in MCF10A cells expressing mutant PIK3CA (H1047R).[1] LINC00520 is upregulated in human tumors and enriched in basal-like human breast carcinomas.[1]
Labs working on this lncRNA
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
- Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
